Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis

Garman, 2004, The molecular defect leading to Fabry disease: structure of human alpha-galactosidase, J. Mol. Biol., 337, 319, 10.1016/j.jmb.2004.01.035 Mehta, 2009, Natural course of Fabry disease: changing pattern of causes of death in FOS — Fabry Outcome Survey, J. Med. Genet., 46, 548, 10.1136/jmg.2008.065904 MacDermot, 2001, Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females, J. Med. Genet., 38, 769, 10.1136/jmg.38.11.769 MacDermot, 2001, Natural history of Fabry disease in affected males and obligate carrier females, J. Inherit. Metab. Dis., 24, 13, 10.1023/A:1012447102358 West, 2009, Agalsidase alfa and kidney dysfunction in Fabry disease, J. Am. Soc. Nephrol., 20, 1132, 10.1681/ASN.2008080870 Sims, 2009, Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry, Stroke, 40, 788, 10.1161/STROKEAHA.108.526293 Branton, 2002, Natural history and treatment of renal involvement in Fabry disease, J. Am. Soc. Nephrol., 13, S139, 10.1097/01.ASN.0000016683.73778.78 Kampmann, 2008, Onset and progression of the Anderson–Fabry disease related cardiomyopathy, Int. J. Cardiol., 130, 367, 10.1016/j.ijcard.2008.03.007 Schiffmann, 2001, Enzyme replacement therapy in Fabry disease: a randomized controlled trial, JAMA, 285, 2743, 10.1001/jama.285.21.2743 Breunig, 2006, Clinical benefit of enzyme replacement therapy in Fabry disease, Kidney Int., 69, 1216, 10.1038/sj.ki.5000208 Mehta, 2009, Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data, Lancet, 374, 1986, 10.1016/S0140-6736(09)61493-8 El Dib, 2013, Enzyme replacement therapy for Anderson-Fabry disease, Cochrane Database Syst. Rev., 2, CD006663 Hughes, 2008, Effects of enzyme replacement therapy on the cardiomyopathy of Anderson–Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa, Heart, 94, 153, 10.1136/hrt.2006.104026 Hernberg-Stahl, 2006, Organization and technical aspects of FOS — the Fabry Outcome Survey Beck, 2004, Fabry disease: overall effects of agalsidase alfa treatment, Eur. J. Clin. Investig., 34, 838, 10.1111/j.1365-2362.2004.01424.x Feriozzi, 2012, The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathy, Clin. J. Am. Soc. Nephrol., 7, 60, 10.2215/CJN.03130411 Schwarting, 2006, Enzyme replacement therapy and renal function in 201 patients with Fabry disease, Clin. Nephrol., 66, 77-74 Linhart, 2007, Cardiac manifestations of Anderson–Fabry disease: results from the international Fabry outcome survey, Eur. Heart J., 28, 1228, 10.1093/eurheartj/ehm153 Mehta, 2004, Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey, Eur. J. Clin. Investig., 34, 236, 10.1111/j.1365-2362.2004.01309.x Banikazemi, 2007, Agalsidase-beta therapy for advanced Fabry disease: a randomized trial, Ann. Intern. Med., 146, 77, 10.7326/0003-4819-146-2-200701160-00148 Schiffmann, 2009, Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy, Nephrol. Dial. Transplant., 24, 2102, 10.1093/ndt/gfp031 2002, K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification, Am. J. Kidney Dis., 39, S1 Devereux, 1992, Left ventricular mass as a measure of preclinical hypertensive disease, Am. J. Hypertens., 5, 175S, 10.1093/ajh/5.6.175S Schiffmann, 2006, Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting, Nephrol. Dial. Transplant., 21, 345, 10.1093/ndt/gfi152 Kampmann, 2009, Effect of agalsidase alfa replacement therapy on Fabry disease-related hypertrophic cardiomyopathy: a 12- to 36-month, retrospective, blinded echocardiographic pooled analysis, Clin. Ther., 31, 1966, 10.1016/j.clinthera.2009.09.008 Zamorano, 2011, Usefulness of tissue Doppler on early detection of cardiac disease in Fabry patients and potential role of enzyme replacement therapy (ERT) for avoiding progression of disease, Eur. J. Echocardiogr., 12, 671, 10.1093/ejechocard/jer109 Rombach, 2013, Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain, Orphanet J. Rare Dis., 8, 47, 10.1186/1750-1172-8-47 Anderson, 2014, Long-term effectiveness of enzyme replacement therapy in Fabry disease: results from the NCS-LSD cohort study, J. Inherit. Metab. Dis., 37, 969, 10.1007/s10545-014-9717-4 Politei, 2014, Fabry disease: multidisciplinary evaluation after 10years of treatment with agalsidase beta, JIMD Rep., 16, 7, 10.1007/8904_2014_310 Weidemann, 2013, Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications, J. Intern. Med., 274, 331, 10.1111/joim.12077